Want to see SE:ANNX full AI Analyst Report?

Annexin Pharmaceuticals AB (ANNX) Price & Analysis

2 Followers

ANNX Stock Chart & Stats

kr13.65

kr0.01(3.44%)

At close: Mar 06 4:00 PM EST

kr13.65

kr0.01(3.44%)

Day’s Range― - ―

52-Week Rangekr11.05 - kr29.36

Previous CloseN/A

Volume76.75K

Average Volume (3M)7.18K

Market Cap

kr110.72M

Enterprise Valuekr81.08

Total Cash (Recent Filing)kr5.27M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.96

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding8,718,182

10 Day Avg. Volume5,478

30 Day Avg. Volume7,183

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)5.25

Price to Sales (P/S)0.00

P/FCF Ratio-3.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetThe absence of reported debt limits interest obligations and reduces leverage-related financial risk. This gives the company greater flexibility to allocate funds toward research and development, although its very small capital base still creates funding concerns.

Targeting High-Need DiseasesThe lead program addresses serious conditions in which inflammation and vascular injury are central mechanisms. If clinical development succeeds, this focused biology could support differentiated positioning in areas with substantial unmet medical need.

Improving Loss And Cash-Burn TrendThe reduction in losses and free cash outflow versus 2024 indicates some improvement in financial performance. While cash generation remains deeply negative, continued operational discipline could extend available resources and moderate funding pressure.

Bears Say

No Revenue GenerationThe absence of reported revenue confirms that the company remains dependent on development-stage assets rather than commercial operations. This leaves future value highly contingent on clinical progress, regulatory success, and eventual product adoption.

Persistent Operating LossesLarge recurring operating and net losses indicate that the current business model does not yet support itself financially. Continued losses will require substantial investment before commercialization and increase sensitivity to delays or unsuccessful pipeline outcomes.

Capital Erosion And Funding RiskRapid erosion of equity and assets alongside persistent cash burn leaves limited internal funding capacity. The company is therefore likely to depend on external financing, creating meaningful dilution and execution risk if capital markets or investor support weaken.

ANNX FAQ

What was Annexin Pharmaceuticals AB’s price range in the past 12 months?

Annexin Pharmaceuticals AB lowest stock price was kr11.05 and its highest was kr29.36 in the past 12 months.

What is Annexin Pharmaceuticals AB’s market cap?

Annexin Pharmaceuticals AB’s market cap is kr110.72M.

When is Annexin Pharmaceuticals AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Annexin Pharmaceuticals AB’s earnings last quarter?

Currently, no data Available

Is Annexin Pharmaceuticals AB overvalued?

According to Wall Street analysts Annexin Pharmaceuticals AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Annexin Pharmaceuticals AB pay dividends?

Annexin Pharmaceuticals AB does not currently pay dividends.

What is Annexin Pharmaceuticals AB’s EPS estimate?

Annexin Pharmaceuticals AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Annexin Pharmaceuticals AB have?

Annexin Pharmaceuticals AB has 8,718,182 shares outstanding.

What happened to Annexin Pharmaceuticals AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Annexin Pharmaceuticals AB?

Currently, no hedge funds are holding shares in SE:ANNX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Annexin Pharmaceuticals AB

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.